Amicus Therapeutics (NASDAQ:FOLD – Get Free Report)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a report issued on Monday,Benzinga reports.
A number of other equities research analysts have also recently commented on FOLD. Guggenheim increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. JPMorgan Chase & Co. increased their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Finally, Bank of America boosted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.88.
Get Our Latest Stock Analysis on Amicus Therapeutics
Amicus Therapeutics Stock Performance
Insider Buying and Selling at Amicus Therapeutics
In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 22,901 shares of company stock worth $259,863 over the last quarter. 2.20% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Amicus Therapeutics
A number of hedge funds have recently made changes to their positions in FOLD. Park Avenue Securities LLC purchased a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $123,000. Diversified Trust Co grew its stake in shares of Amicus Therapeutics by 9.7% in the fourth quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company’s stock valued at $770,000 after buying an additional 7,257 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at $107,000. Old West Investment Management LLC lifted its stake in Amicus Therapeutics by 617.2% during the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock worth $3,636,000 after acquiring an additional 292,976 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new position in Amicus Therapeutics during the 3rd quarter valued at about $702,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Read More
- Five stocks we like better than Amicus Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Stock Market Upgrades: What Are They?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.